CH675727A5 - - Google Patents

Download PDF

Info

Publication number
CH675727A5
CH675727A5 CH5119/86A CH511986A CH675727A5 CH 675727 A5 CH675727 A5 CH 675727A5 CH 5119/86 A CH5119/86 A CH 5119/86A CH 511986 A CH511986 A CH 511986A CH 675727 A5 CH675727 A5 CH 675727A5
Authority
CH
Switzerland
Prior art keywords
cells
polypeptide
sep
proliferation
oncostatin
Prior art date
Application number
CH5119/86A
Other languages
German (de)
English (en)
Inventor
Joyce M Zarling
Mohammed Shoyab
Hans Marquardt
Marcia B Hanson
Mario N Lioubin
Thomas Joseph Brown
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of CH675727A5 publication Critical patent/CH675727A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CH5119/86A 1985-12-20 1986-12-22 CH675727A5 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81123585A 1985-12-20 1985-12-20
US93528386A 1986-11-26 1986-11-26

Publications (1)

Publication Number Publication Date
CH675727A5 true CH675727A5 (pt) 1990-10-31

Family

ID=27123452

Family Applications (1)

Application Number Title Priority Date Filing Date
CH5119/86A CH675727A5 (pt) 1985-12-20 1986-12-22

Country Status (29)

Country Link
JP (1) JP2559035B2 (pt)
KR (1) KR920005920B1 (pt)
CN (1) CN1017626B (pt)
AT (1) AT400444B (pt)
AU (2) AU601168B2 (pt)
BE (1) BE905957A (pt)
CA (1) CA1340296C (pt)
CH (1) CH675727A5 (pt)
CY (1) CY1608A (pt)
DE (2) DE3643428A1 (pt)
DK (1) DK174094B1 (pt)
ES (1) ES2003180A6 (pt)
FI (1) FI91484C (pt)
FR (1) FR2597108B1 (pt)
GB (1) GB2185485B (pt)
GR (1) GR862936B (pt)
HK (1) HK65691A (pt)
HU (1) HU210694B (pt)
IE (1) IE59415B1 (pt)
IL (1) IL81017A (pt)
IT (1) IT1213428B (pt)
LU (1) LU86718A1 (pt)
NL (1) NL8603209A (pt)
NO (1) NO174556C (pt)
NZ (1) NZ218634A (pt)
OA (1) OA08494A (pt)
PT (1) PT83986B (pt)
SE (1) SE505059C2 (pt)
SG (1) SG60891G (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits
US5681930A (en) * 1985-12-20 1997-10-28 Bristol-Myers Squibb Company Anti-oncostatin M monoclonal antibodies
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
ZA912137B (en) * 1990-03-29 1992-11-25 Oncogen Monocional antibodies that inhibit growth of kaposi's sarcoma
NZ237533A (en) * 1990-03-29 1992-12-23 Bristol Myers Squibb Co Monoclonal antibodies which bind to oncostatin m, cell lines producing them
WO1992002556A1 (en) * 1990-08-02 1992-02-20 Michael Valentine Agrez Human colon cancer cell-derived fibroblast elongation factor
IL107040A0 (en) * 1992-09-25 1993-12-28 Lilly Co Eli Modified platelet factor-4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132776A (en) * 1978-02-15 1979-01-02 University Patents, Inc. Delivery of immunologically active components of transfer factor
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits

Also Published As

Publication number Publication date
IL81017A0 (en) 1987-03-31
LU86718A1 (fr) 1988-07-14
FI91484C (fi) 1994-07-11
IT8622787A0 (it) 1986-12-19
DE3643428C2 (pt) 1990-08-23
DE3643428A1 (de) 1987-09-24
ATA340686A (de) 1995-05-15
SG60891G (en) 1991-08-23
HUT43103A (en) 1987-09-28
OA08494A (fr) 1988-07-29
CA1340296C (en) 1998-12-29
HK65691A (en) 1991-08-23
ES2003180A6 (es) 1988-10-16
NO865178D0 (no) 1986-12-19
SE8605459L (sv) 1987-06-21
GR862936B (en) 1987-10-28
IE59415B1 (en) 1994-02-23
AU6776590A (en) 1991-03-14
CN86108955A (zh) 1987-12-02
DE3645095C2 (de) 1993-11-18
GB8629997D0 (en) 1987-01-28
AU639048B2 (en) 1993-07-15
FR2597108A1 (fr) 1987-10-16
SE505059C2 (sv) 1997-06-16
DK615386D0 (da) 1986-12-18
PT83986B (pt) 1989-07-31
SE8605459D0 (sv) 1986-12-18
GB2185485A (en) 1987-07-22
NO865178L (no) 1987-06-22
DK615386A (da) 1987-06-21
AU6660886A (en) 1987-06-25
IE863345L (en) 1987-06-20
AT400444B (de) 1995-12-27
NO174556B (no) 1994-02-14
NZ218634A (en) 1991-06-25
JPS62236498A (ja) 1987-10-16
FI91484B (fi) 1994-03-31
AU601168B2 (en) 1990-09-06
BE905957A (fr) 1987-06-17
FI865156A (fi) 1987-06-21
FI865156A0 (fi) 1986-12-17
PT83986A (en) 1987-01-01
CN1017626B (zh) 1992-07-29
HU210694B (en) 1995-06-28
KR870005645A (ko) 1987-07-06
KR920005920B1 (ko) 1992-07-24
GB2185485B (en) 1990-07-04
NL8603209A (nl) 1987-07-16
FR2597108B1 (fr) 1991-02-15
IL81017A (en) 1993-01-14
JP2559035B2 (ja) 1996-11-27
NO174556C (no) 1994-05-25
IT1213428B (it) 1989-12-20
DK174094B1 (da) 2002-06-10
CY1608A (en) 1992-04-03

Similar Documents

Publication Publication Date Title
DE69028671T3 (de) Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung
DE69032086T2 (de) Zytotoxischer Lymphozyten-Reifefaktor
DE69014474T2 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
DE69017753T2 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper.
DE3686927T2 (de) Neovaskularisierungsinhibitoren und deren herstellung.
DE68928641T2 (de) Menschliches IFN-beta2/IL-6, dessen Reinigung und Verwendungen
DE3650788T2 (de) Produktion des pluripotenten Granulozyten-Koloniestimulierungsfaktors
DE69030956T2 (de) Inhibierung des Transformierenden Wachstumsfaktors zur Verhinderung der Anhäufung Extrazellulärer Matrix
DE3586536T2 (de) Monoklonaler antikoerper gegen ein cytotoxin, denselben erzeugendes hybridoma und verfahren fuer die herstellung des gereinigten cytotoxin.
DE3689246T2 (de) Physiologisch aktives Polypeptid BUF-3.
DE68925935T2 (de) Antikörper gegen Interleukin-1-beta
EP0705846B1 (de) Hochmolekulare und niedermolekulare Fraktionen des von Willebrand-Faktors
DE68920931T2 (de) Rekombinanter natürlicher Killerzellen-Aktivator.
CH675727A5 (pt)
DE69021128T2 (de) Interleukin-1-Inhibitor.
DE69029040T2 (de) Megakaryocytopoietischer faktor
DE68928138T2 (de) Neuer megakaryokytischer koloniestimulierender faktor und verfahren zur herstellung
EP0354934A1 (de) Neutrophilen aktivierendes polypeptid, verfahren zu dessen herstellung sowie dessen verwendung als arzneimittel und diagnostikum
DE69026077T2 (de) Medizinische verwendung von m-csf
Newcom et al. High molecular weight transforming growth factor β is excreted in the urine in active nodular sclerosing Hodgkin's disease
EP0452849A1 (de) Monoklonale Antikörper gegen PP4, Verfahren zu ihrer Herstellung und ihre Verwendung
DE3880758T2 (de) Von monozyten abstammendes gefaesswirksames protein und dessen analogen, verfahren zu seiner gewinnung und ihre verwendungen fuer therapeutische zwecke und zur antikoerperherstellung.
DE69017707T2 (de) Kontrolle der milchsekretion.
DE68911305T2 (de) Das lungenwachstum stimulierende und hemmende faktoren für krebstumorzellen.
DE19919148A1 (de) Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere